echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Asia-Pacific Pharmaceuticals Receives Acceptance Notice for Consistency Evaluation of Terazosin Hydrochloride Tablets

    Asia-Pacific Pharmaceuticals Receives Acceptance Notice for Consistency Evaluation of Terazosin Hydrochloride Tablets

    • Last Update: 2021-12-29
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On December 9, Asia-Pacific Pharmaceuticals issued an announcement stating that it had recently received an acceptance notice on the consistency evaluation of terazosin hydrochloride tablets issued by the National Medical Products Administration


    Oral administration of terazosin hydrochloride tablets is suitable for the treatment of mild or moderate hypertension, and can be used in combination with thiazide diuretics or other antihypertensive drugs, and can also be used alone when other drugs are not applicable or ineffective


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.